A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.
Pyrilutamide shows minimal systemic absorption with low plasma levels and no accumulation, suggesting it's unlikely to cause systemic side effects. However, full results are not yet published in scientific journals.
The conversation discusses alternatives to finasteride for hair loss, including topical treatments like minoxidil, RU58841, CB-03-01, and dutasteride. Users also mention other options like alfatradiol, topical caffeine, and mesotherapy, while expressing concerns about side effects and the effectiveness of these treatments.
The user added 0.5mg dutasteride to their regimen of topical finasteride and minoxidil but experienced rapid hairline recession despite reduced hair fall. Suggestions included increasing the dutasteride dosage to 1mg daily to better suppress DHT and potentially adding oral minoxidil.
The user has been using finasteride and minoxidil for 5 years with initial success but is now experiencing hair thinning despite increasing dutasteride usage. They are considering adjusting dutasteride frequency and possibly adding treatments like eucapil, minoxidil, and GHK-Cu peptides.
Topical dutasteride may have limited absorption due to its higher molecular mass compared to finasteride, potentially affecting its efficacy in suppressing DHT locally. Microneedling might enhance dutasteride absorption, possibly offering stronger local DHT suppression with fewer systemic effects.
Aminexil, nanoxidil, stemoxydine, and kopexil are discussed as alternatives to minoxidil for hair growth, with concerns about dependence. Minoxidil is noted for its effectiveness in transitioning hair growth phases, but dependence is mainly linked to androgenic alopecia.